Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2080220076
JPRN-jRCT2080220076
Unknown
Phase 2

A phase 2 study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced, metastatic or recurrent non-small cell lung cancer.(JO16565)

Chugai Pharmaceutical Co., Ltd.0 sitesSeptember 9, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAdvanced or metastatic or recurrent non-small cell lung cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Advanced or metastatic or recurrent non-small cell lung cancer
Sponsor
Chugai Pharmaceutical Co., Ltd.
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 9, 2005
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •patients with advanced/metastatic or recurrent NSCLC (stage IIIB or IV) who have failed at least one previous platinum chemotherapy regimen.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Phase 2
A phase II study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced/metastatic or recurrent non-small cell lung cancer. (JO18396)Advanced or metastatic or recurrent non-small cell lung cancer
JPRN-jRCT2080220075Chugai Pharmaceutical Co., Ltd.
Not yet recruiting
Phase 2
Comparison of two ways of using medications for preventing graft versus host disease after a half-matched stem cell transplantHealth Condition 1: C920- Acute myeloblastic leukemia
CTRI/2024/06/068451Indian Council of Medical Research
Active, not recruiting
Phase 1
Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-001241-84-GBovartis Pharma Services AG23
Active, not recruiting
Phase 1
Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-001241-84-FRovartis Pharma Services AG23
Active, not recruiting
Phase 1
Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 19.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-001241-84-PTovartis Pharma Services AG135